Abiopharma

🔍 Stuglik Brian M (Director)

Company: PUMA BIOTECHNOLOGY, INC. (PBYI)

Report Date: 2026-06-11

Detailed Transactions and Holdings:

• Acquired 27,000 shares of Common Stock (Direct)
  Date: 2026-06-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 121,958.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 8,100 shares of Common Stock at $7.1989 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 113,858.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
• F2: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.